| Drug Name | ( Xigduo XR (Dapagliflozin / Metformin |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with inhibitors (SGLT2i) Risk of diabetic ketoacidosis |
| Dear Healthcare provider letter DHPC |
|